• 關於我們
  • 關於我們
選擇您的偏好語言
Englishlocale_code=zh-HK
中國香港 (locale_code=zh-HK)
更改國家/地區
  • 關於我們
  • 新聞中心
  • 投資者關係
  • 招賢納士
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
  • 消費者產品消費者產品
    • 消費者支援
    • 產品註冊
    • My Philips
  • 專業醫療專業醫療
    • 專業醫療支持
  • 其他業務解決方案​其他業務解決方案​
    • 照明業務
    • 汽車
    • 聽力解決方案
    • 更多
    • 專業的顯示器方案
    • 專業語音記錄解決方案
  • 關於我們關於我們
    • 新聞
    • 投資者關係
    • 招賢納士
    • 更多
    • 環境、社會和管理​
    • 創新​
  • 訂閱訂閱
    • 專業醫療最新資訊
    • 公司動態及新聞稿
  • 獲取最新資訊獲取最新資訊
    • 選擇您的地區及語言香港特別行政區 (繁體中文)
    • 私隱須知
    • 使用條款
    • Cookie 聲明
    © Koninklijke Philips N.V., 2004 - 2026。 版權所有。
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌
    ‌

    Philips expands global access to its ground-breaking 3D intracardiac echocardiography to Hong Kong

    • May 24, 2024
    • 2 分鐘閱讀

    心內科

    圖像引導治療

    新聞稿

    一覽

    • Hong Kong selected as the pioneering international location for integrating Philips’ VeriSight Pro 3D Intracardiac Echocardiography (ICE) catheter into routine clinical practice

    • International roll-out underscores Philips’ commitment to driving healthcare innovation and enhancing patient outcomes worldwide

    Amsterdam, the Netherlands and Hong Kong – Royal Philips, a global leader in health technology, today announced that the first hospitals in Hong Kong have started using Philips real-time 3D Intracardiac Echocardiography (ICE) catheter – VeriSight Pro – to aid minimally-invasive image-guided procedures. It is the first time the VeriSight Pro catheter, which is guided through a patient’s blood vessels until it lies directly inside the chambers of the heart, has been used clinically outside the US or Canada. It marks the start of the international roll-out of the company’s ground-breaking ICE imaging technology. VeriSight Pro’s high-quality imaging is particularly effective in planning and guiding complicated interventional procedures.

     VeriSight Pro intracardiac echocardiography catheter

    “The VeriSight Pro 3D ICE catheter delivers the image quality we need to characterize otherwise difficult-to-image heart structures such as the left atrial appendage or tricuspid valve, allowing us to achieve more advanced procedural imaging for our patients,” said Dr. Michael Lee, Head of Cardiology at Queen Elizabeth Hospital, Hong Kong. “Philips has taken us up the learning curve remarkably quickly, so we can use it safely and confidently.”

    Hong Kong hospitals participating in VeriSight Pro’s international roll-out include the Queen Elizabeth Hospital, Queen Mary Hospital, Prince of Wales Hospital, Hong Kong Asia Heart Centre, Hong Kong Sanatorium & Hospital, and Hong Kong Adventist Hospital. Last month, several of them began using the Philips real-time 3D ICE catheter – VeriSight Pro – under the expert guidance of Professor Gagan Singh and Dr. Edris Aman, who has pioneered the use of intracardiac echocardiography at the University of California Davis Health (Sacramento, CA, USA) for the past two years.

    Offering superior 2D and 3D live imaging, VeriSight Pro allows interventionalists to navigate procedures easily and optimize interventional suite performance. The reduced need for sedation or general anesthesia accelerates workflows, increasing procedure efficiency and reducing procedure times [1]. VeriSight Pro is designed for use with Philips’ premium ultrasound systems, EPIQ CVx, and EPIQ CVxi.

    “At Philips, we are committed to delivering state-of-the-art imaging solutions such as VeriSight Pro that leverage the advanced capabilities of our EPIQ ultrasound platform to enhance procedural confidence, optimize patient outcomes, and set new global standards in care,” said Bert van Meurs, Chief Business Leader of Precision Diagnosis and Image-Guided Therapy at Philips. “We look forward to working with leading specialists around the world to make that happen.”

    Based on Philips’ innovative xMATRIX array 3D steerable beam ultrasound transducer technology, the VeriSight Pro 3D ICE captures high-quality 2D and 3D live images of the heart, including a 90-degree by 90-degree 3D field of view. Simultaneous viewing of two scan planes (for example, to measure the long and short axes of the left atrial appendage), plus 3D volume and color-flow images, adds valuable information.

    Philips Intracardiac Echocardiography Catheter – VeriSight Pro – adds to the company’s comprehensive suite of integrated ultrasound imaging solutions, which combine interventional X-ray, 3D ultrasound, and related interventional tools to enable confident navigation and positioning of devices and reduce procedure times.

    來源

    1. Diaz JC, Bastidas O, Duque M, et al. Impact of intracardiac echocardiography versus transesophagealechocardiography guidance on left atrial appendage occlusion procedures: A meta‐analysis. J. Cardiovasc. Electrophysiol. 2024; 35(1)44-57.2

    荷蘭皇家飛利浦集團(NYSE交易代號:PHG;AEX交易代號:PHIA)是一家領先的健康科技公司,致力透過具意義的創新改善人們的健康和福祉。飛利浦以病人及人為本,結合先進科技、深厚的臨床專業知識及對消費者的深入了解,為消費者提供個人健康解決方案,並為醫療專業人員及其病人提供專業健康科技方案,涵蓋醫院及家居護理環境。總部設於荷蘭,飛利浦在影像診斷、超聲波、圖像引導治療、病人監護及醫療資訊系統,以及個人健康領域均處於領導地位。飛利浦於2025年錄得180億歐元銷售額,全球約有64,300名員工,銷售及服務網絡遍及100多個國家。有關飛利浦的新聞,請瀏覽:www.philips.com.hk/a-w/about/news/home

    媒體資源

    • VeriSight Pro intracardiac echocardiography catheter

      VeriSight Pro intracardiac echocardiography catheter

    媒體聯絡

    Philips shield logo

    企業傳訊

    聯絡資料

    分享到社交媒體